Web Exclusives

Results from an incidental lung nodule program implemented in a community healthcare system demonstrates this program detects lung cancer in patients who are otherwise ineligible for LDCT screening.

Patients with advanced KRAS^G12C harboring NSCLC maintained quality of life and physical functioning with tolerable side effects while being treated with sotorasib.

Data indicate a steady improvement over the past decade in NSCLC survival rates due to immunotherapy and targeted therapy.

A recent review article provided best practices for biomarker testing and recommendations for the diagnosis and management of patients with advanced NSCLC.

Treatment timing and type at time of diagnosis of stage III NSCLC influences patients’ overall survival, with gender and race differences also influencing therapy.

Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant accelerated approval for sotorasib for patients with KRAS^G12C-mutated NSCLC.

The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.

Sotorasib has shown promising antitumor activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.

Recently released survey responses identified multiple barriers to, and dissatisfaction with, the current state of molecular testing in lung cancer.

An investigational treatment for second-line treatment of NSCLC was found to be well tolerated and active against KRAS mutations, according to the results of a new study.

To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical.

Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial.

Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness.

The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers.

Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors.

Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer.

Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab.

Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies.

Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy.

Telemedicine may play a critical role by creating pathways for overcoming obstacles to healthcare access, particularly for breast cancer reconstruction.

Preliminary recommendations made based on cases from the SOLAR-1 trial suggest that alpelisib-induced hyperglycemia can be managed with early detection, close monitoring, and prompt intervention.

For patients with early HR-positive, HER2-positive breast cancer who initiated neratinib within 1 year of completing trastuzumab and in patients who did not achieve a pathologic complete response after neoadjuvant treatment, neratinib may be a cost-effective treatment option.

Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.

The combination of exemestane and entinostat did not show survival benefit in patients with aromatase inhibitor–resistant, HR-positive, HER2-negative advanced breast cancer.

Subgroup analysis of the phase 3b CompLEEment-1 clinical trial supports the use of ribociclib combined with letrozole in HR-positive, HER2-negative advanced breast cancer male patients based on demonstrated efficacy and safety.